The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Peptide Therapeutics For The Treatment Of Autoimmune Diseases: Stability, Delivery And Disposition
Funder
National Health and Medical Research Council
Funding Amount
$368,467.00
Summary
Autoimmune diseases affect around 120 million people worldwide. This project will progress the development of a peptide that suppresses disease-causing autoantigen-specific immune responses without affecting protective responses. Different routes of delivery for this peptide will be evaluated, as well as slow-release formulations that will extend its in vivo lifetime. The outcome will be a patient-friendly form of this therapeutic lead that can be taken forward to preclinical evaluation.
TBK1 Inhibitors As Novel Therapeutics For Rheumatoid Arthritis
Funder
National Health and Medical Research Council
Funding Amount
$511,722.00
Summary
A key feature of rheumatoid arthritis is inflammation in affected joints causing pain and immobility. New drugs that selectively block processes that are dysregulated in rheumatoid arthritis are needed to better treat this disease. The protein called TBK1 is a key regulator of inflammation and we aim to develop drugs that inhibit TBK1 activity thereby blocking the inflammation and symptoms associated with rheumatoid arthritis.
Pancreatic Targeting Of IL-22 Therapy For Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$484,644.00
Summary
Type 2 diabetes is one of the largest problems facing health care and presents an enormous therapeutic market. Our approach with IL-22 fights the disease at the core of the problem in the pancreatic ?-cells that make insulin. Our patent focuses on targeting IL-22 to the ?-cells which promises to maximise therapeutic benefits while minimising potential adverse effects in other tissues. Independently, and in collaboration with Novo Nordisk, we are making prototype drugs to achieve this.
Development Of A Modified Gp130 Ligand To Treat Obesity-induced Insulin Resistance
Funder
National Health and Medical Research Council
Funding Amount
$438,533.00
Summary
IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in tr ....IC7 is a mixture of two naturally occurring proteins, CNTF and IL-6. These gp130 receptor ligands have been shown to have positive metabolic effects in humans, but individually they are not suitable for therapeutic use. IC7, the novel molecule this technology is based upon, is a combination of CNTF and IL-6 in a specific design to avoid the negative effects. Preliminary results suggest that IC7 has positive metabolic effects but further development is required to increase its effectiveness in treating insulin resistance and type 2 diabetes.Read moreRead less
In Vitro Diagnostic For First Trimester Risk Assignment Of Gestational Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$580,983.00
Summary
Pregnancy associated diabetes is a significant complication of pregnancy that has adverse health effects for both mother and baby. We have developed a multivariate algorithm to identify women during their first trimester of pregnancy who will subsequently develop gestational diabetes. The test requires further clinical validation to develop a commercial product and to implement it into clinical practice.
A portable device that can measure glycosylated haemoglobin (HbA1c) in the home will be developed. HbA1c is an important biomarker of the average blood glucose levels over the preceding three months and hence guides a diabetic regarding their blood glucose treatment regime. A 1% decrease in HbA1c levels is associated with a dramatic decrease in chronic health complications from diabetes. The HbA1c meter that will be developed will be able to operate with existing glucose meter technologies.
Harnessing Anticalin Technology As A Multi-targeted Treament Approach For Vision Loss
Funder
National Health and Medical Research Council
Funding Amount
$627,273.00
Summary
Diabetes is a leading cause of vision loss and blindness worldwide and is caused by two factors called VEGF and Ang2, which damage blood vessels. Current treatments only block VEGF and many patients do not respond and suffer irreversible damage to sight. We have used ground-breaking anticalin technology to make a new drug (PRS-AUS1) that blocks both VEGF and Ang2. Studies will be performed in animal models and move to patients where we expect improved outcomes compared to current treatments.